We’re heading #AAIC2024 in Philadelphia, PA, July 28 - August 1. Visit us at booth 920A to learn about oral ALZ-801 and our relentless pursuit to defeat #Alzheimer’s. We hope to see you there! 🧠 #EndAlz Alzheimer's Association® https://t.ly/EPKri
Alzheon, Inc. | Preserving Future Memories
Biotechnology Research
Framingham, MA 4,770 followers
Developing treatments to slow or stop Alzheimer’s disease & other devastating neurological disorders
About us
Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and efficacy profile of its active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com
- Website
-
http://www.alzheon.com
External link for Alzheon, Inc. | Preserving Future Memories
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Framingham, MA
- Type
- Privately Held
- Founded
- 2013
- Specialties
- Alzheimer's disease, Drug development, Neurodegeneration, and Biotechnology
Locations
-
Primary
Get directions
111 Speen Street, Suite 306
Framingham, MA 01701, US
Employees at Alzheon, Inc. | Preserving Future Memories
-
Martin Tolar, MD, PhD
Founder, President & CEO at Alzheon, Inc. | Founder & Chairman at INDRC | Alzheimer’s Disease Research
-
Jean Schaefer
VP CMC Operations & Project Management at Alzheon, Inc. | Preserving Future Memories | Helping Cross-functional Teams Succeed
-
Audrey Rossow
Experienced Senior Clinical Operations and Project Management Leader
-
Glenn E. Pauly
Chief Commercial Officer (Alzheon)
Updates
-
🧠 Two Alzheon Publications Report Alzheimer’s Biomarker, Brain Preservation, and Clinical Outcomes Following 2 Years of Treatment in Phase 2 Trial of oral ALZ-801. #Alzheimer's #dementia Press release link: https://t.ly/vhpun
-
We are thrilled to join BrightFocus Foundation for their June 20 episode of Zoom In on Alzheimer’s & Dementia to discuss the importance of understanding your genetic risk for Alzheimer’s and related dementias. Register to join the conversation and live Q&A: brightfocus.org/ADZoom #dementia #Alzheimer's
-
-
We are thrilled to announce our successful Series E funding round of $100M! This achievement brings us closer to preserving future memories, but we know it will take continued hard work and strong partnerships. We’ve received numerous congratulatory messages from around the world encouraging us to keep pushing forward. Check out this one from the New York Stock Exchange. Thank you, NYSE! We are committed to advancing the development of our lead asset, ALZ-801.
-
-
🚀 Alzheon secures $100M Series E funding! Advancing the development & commercialization of ALZ-801/valiltramiprosate, a promising oral treatment for #Alzheimer's disease. 🧠 #dementia https://lnkd.in/eF5zTb3B
-
In our "THINKING OUT LOUD LEARNING SERIES": The number of people with #dementia is estimated to grow from 55 million in 2019 to 139 million by 2050. Stay informed about the rising impact of dementia worldwide. #ENDALZ #alzheimersdisease
-
-
Another edition of our "THINKING OUT LOUD LEARNING SERIES": In 2023, #Alzheimer's and other dementias cost the nation $345 billion. By 2050, these costs could rise to nearly $1 trillion. Stay informed about the economic impact of #dementia. #ENDALZ 💭🌍 alz.org/facts
-
-
Join Our Quality Team at Alzheon! Passionate about making a difference in neurodegenerative disease research? We're looking for dedicated individuals to join our Quality Team at Alzheon! If you're committed to excellence and want to contribute to groundbreaking therapies for Alzheimer's and related disorders, apply today! https://lnkd.in/eM77wxkH #Alzheoncareers #quality #GMP #QA #CQA
-
-
In our ongoing "THINKING OUT LOUD LEARNING SERIES," let's reflect: Every 3 seconds, someone in the world develops dementia. It's more than a statistic; it's a reality. Join us as we continue our series for understanding, empathy, and advocacy. Together, let's make a difference. #alzheimers #dementia 🌍
-
-
Exciting news! The first patient has been dosed in our Long-Term Extension (LTE) of APOLLOE4 Ph 3 Trial for Oral ALZ-801/Valiltramiprosate. We also launched a 52-week extension of our Ph 2 Biomarker Trial for Early AD. Progress in the fight against #Alzheimer's continues! #ENDALZ